These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8357303)

  • 21. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
    Spruss T; Gust R; Müller R; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 3. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of 2,2'-disubstituted butestrols and 6,6'-disubstituted metabutestrols.
    Hartmann RW; Heindl A; Schwarz W; Schönenberger H
    J Med Chem; 1984 Jul; 27(7):819-24. PubMed ID: 6330356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Spruss T; Maucher A; von Angerer E; Schiller CD; Schneider MR; Gust R; Schönenberger H
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):153-67. PubMed ID: 17024493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the configurational and conformational influences on the hormonal activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes. 1. Synthesis, estradiol receptor affinity, and estrogenic activity of diastereomeric [N-alkyl- and N,N'-dialkyl-1,2- bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 1995 Jun; 38(12):2070-9. PubMed ID: 7783138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes.
    Dullin A; Dufrasne F; Gelbcke M; Gust R
    ChemMedChem; 2006 Jun; 1(6):644-53. PubMed ID: 16892405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes.
    Hartmann RW; Schwarz W; Heindl A; Schönenberger H
    J Med Chem; 1985 Sep; 28(9):1295-301. PubMed ID: 2993619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
    Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
    J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 2. Synthesis and estrogen receptor binding affinity of 4,4'-, 5,5'-, and 6,6'-disubstituted metahexestrols.
    Hartmann RW; Heindl A; Schönenberger H
    J Med Chem; 1984 May; 27(5):577-85. PubMed ID: 6325689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
    Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
    J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma.
    Wappes B; Jennerwein M; von Angerer E; Schönenberger H; Engel J; Berger M; Wrobel KH
    J Med Chem; 1984 Oct; 27(10):1280-6. PubMed ID: 6481764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studies.
    Bernhardt G; Koch M; Spruss T; Gust R; Krauser R; Schlemmer R; Hollstein M; Lux F; Schönenberger H
    Arch Pharm (Weinheim); 1999 Jun; 332(6):195-200. PubMed ID: 10399488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
    Hartmann RW; Buchborn H; Kranzfelder G; Schönenberger H; Bogden A
    J Med Chem; 1981 Oct; 24(10):1192-7. PubMed ID: 6276542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.
    Otto AM; Kratochwil NA; Eggers H; Bednarski PJ
    J Cancer Res Clin Oncol; 1995; 121(1):31-8. PubMed ID: 7860616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(ii) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(ii) complexes in relation to the complex structure.
    Konovalov B; Živković MD; Milovanović JZ; Djordjević DB; Arsenijević AN; Vasić IR; Janjić GV; Franich A; Manojlović D; Skrivanj S; Milovanović MZ; Djuran MI; Rajković S
    Dalton Trans; 2018 Oct; 47(42):15091-15102. PubMed ID: 30303498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, conformational studies, and investigations on the estrogen receptor binding of [R/S-1-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]platinum(II) complexes.
    Gust R; Lubczyk V; Schmidt K; Shihada U
    Arch Pharm (Weinheim); 2001 Mar; 334(3):93-100. PubMed ID: 11315340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
    Knebel NG; von Angerer E
    J Med Chem; 1991 Jul; 34(7):2145-52. PubMed ID: 2066987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.